NextFin News - CVS Health will restore coverage of Eli Lilly’s blockbuster weight-loss injection Zepbound and add its newly approved obesity pill, Foundayo, to its standard commercial drug plans, reversing a major exclusion that previously shut Lilly out of one of the nation’s largest insurance templates. According to CNBC, CVS Caremark, the pharmacy benefit management arm of CVS Health, will add Zepbound to its standard commercial formulary on October 1, 2026, while Lilly’s oral treatment Foundayo will gain coverage on June 1, 2026. The decision places Lilly on equal footing with its chief rival, Novo Nordisk, whose injection Wegovy had enjoyed exclusive preferred status on the CVS template since an exclusive deal was struck in May 2025.
The shift to a co-preferred model for both Lilly and Novo Nordisk medications represents a tactical pivot for CVS Caremark, which manages prescription benefits for approximately 25 million to 30 million Americans. A year ago, the pharmacy benefit manager sought to exploit its massive scale by choosing Wegovy as its sole preferred obesity treatment, effectively forcing Lilly to negotiate from a position of weakness. By bringing Zepbound back and embracing Foundayo, CVS expects the renewed competition between the two pharmaceutical giants to drive an additional 10% to 15% in savings across its weight management category, according to the company's announcement.
However, the promise of double-digit savings comes with significant caveats for both employers and patients. While CVS Caremark’s standard formulary serves as a blueprint, individual plan sponsors—the employers and insurers who fund these benefits—retain the right to opt out of covering GLP-1 weight-loss medications entirely. Many corporate benefit managers have expressed growing alarm over the sheer volume of employees seeking these treatments, which can cost upwards of $1,000 a month per patient before discounts. Consequently, co-preferred status on a template does not guarantee that every eligible patient will see their out-of-pocket costs decline or their coverage approved.
Industry critics also question whether the pharmacy benefit manager-driven competition truly benefits the end consumer. Independent healthcare policy researchers, such as those at the Kaiser Family Foundation, have long pointed out that these intermediaries often favor drugs with higher list prices and larger manufacturer rebates over lower-cost alternatives. Because rebates are typically shared between the pharmacy benefit manager and the employer rather than passed directly to the patient at the pharmacy counter, the actual net cost reduction for individual patients remains highly variable. The inclusion of Foundayo, Lilly’s newly approved oral treatment, could alter this dynamic by offering a more convenient, potentially less expensive alternative to weekly injections, though its long-term market adoption and pricing structure are still being evaluated by commercial insurers.
For Eli Lilly, the decision is an undeniable commercial victory. The exclusion from CVS’s standard plans in 2025 was a painful blow that temporarily ceded market share to Novo Nordisk in the highly lucrative U.S. anti-obesity market. Regaining access to CVS Caremark’s massive commercial block allows Lilly to fully deploy its expanded manufacturing capacity, which has struggled to keep pace with overwhelming demand over the past two years. The addition of Foundayo further diversifies Lilly's portfolio, giving it a head start in the emerging market for oral weight-loss therapies before Novo Nordisk can launch its own pill formulations on a similar scale.
With Zepbound set to return to the formulary in October and Foundayo arriving in June, the battle for dominance in the multi-billion-dollar weight-loss market is entering a more aggressive phase, where pricing concessions and supply-chain reliability will ultimately dictate which drugmaker captures the lion's share of American prescriptions.
Explore more exclusive insights at nextfin.ai.
